Patents by Inventor Mahmoud S. AlSwisi

Mahmoud S. AlSwisi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antioxidant stabilized pharmaceutical formulations comprising antineoplastic compounds
    Patent number: 9211336
    Abstract: The present invention relates to stabilized pharmaceutical formulations prepared from solutions comprising an antineoplastic compound having a cyclic or non-cyclic hydrazine, triazine, or tetrazine group, or a pharmaceutically acceptable salt thereof, and a stabilizer, wherein the stabilizer is an antioxidant and/or more susceptible to nucleophilic attack than the antineoplastic compound.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: December 15, 2015
    Assignee: HIKMA PHARMACEUTICALS
    Inventors: Mahmoud S. AlSwisi, Mahmoud A. A. Ghannam
  • Stabilized pharmaceutical formulations comprising antineoplastic compounds
    Patent number: 9211335
    Abstract: The present invention relates to stabilized pharmaceutical formulations prepared from solutions comprising an antineoplastic compound having a cyclic or non-cyclic hydrazine, triazine, or tetrazine group, or a pharmaceutically acceptable salt thereof, and a stabilizer, wherein the stabilizer is an antioxidant and/or more susceptible to nucleophilic attack than the antineoplastic compound.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: December 15, 2015
    Assignee: Hikma Pharmaceuticals
    Inventors: Mahmoud S. AlSwisi, Mahmoud A. A. Ghannam
  • STABILIZED PHARMACEUTICAL FORMULATIONS COMPRISING ANTINEOPLASTIC COMPOUNDS
    Publication number: 20150148391
    Abstract: The present invention relates to stabilized pharmaceutical formulations prepared from solutions comprising an antineoplastic compound having a cyclic or non-cyclic hydrazine, triazine, or tetrazine group, or a pharmaceutically acceptable salt thereof, and a stabilizer, wherein the stabilizer is an antioxidant and/or more susceptible to nucleophilic attack than the antineoplastic compound.
    Type: Application
    Filed: February 3, 2015
    Publication date: May 28, 2015
    Inventors: Mahmoud S. AlSwisi, Mahmoud A.A. Ghannam
  • Stabilized pharmaceutical formulations comprising antineoplastic compounds
    Patent number: 8974811
    Abstract: The present invention relates to stabilized pharmaceutical formulations prepared from solutions comprising an antineoplastic compound having a cyclic or non-cyclic hydrazine, triazine, or tetrazine group, or a pharmaceutically acceptable salt thereof, and a stabilizer, wherein the stabilizer is an antioxidant and/or more susceptible to nucleophilic attack than the antineoplastic compound.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: March 10, 2015
    Assignee: Hikma Pharmaceuticals
    Inventors: Mahmoud S. AlSwisi, Mahmoud A. A. Ghannam
  • STABILIZED PHARMACEUTICAL FORMULATIONS COMPRISING ANTINEOPLASTIC COMPOUNDS
    Publication number: 20140309197
    Abstract: The present invention relates to stabilized pharmaceutical formulations prepared from solutions comprising an antineoplastic compound having a cyclic or non-cyclic hydrazine, triazine, or tetrazine group, or a pharmaceutically acceptable salt thereof, and a stabilizer, wherein the stabilizer is an antioxidant and/or more susceptible to nucleophilic attack than the antineoplastic compound.
    Type: Application
    Filed: June 25, 2014
    Publication date: October 16, 2014
    Inventors: Mahmoud S. AlSwisi, Mahmoud A.A. Ghannam
  • STABILIZED PHARMACEUTICAL FORMULATIONS COMPRISING ANTINEOPLASTIC COMPOUNDS
    Publication number: 20140275195
    Abstract: The present invention relates to stabilized pharmaceutical formulations prepared from solutions comprising an antineoplastic compound having a cyclic or non-cyclic hydrazine, triazine, or tetrazine group, or a pharmaceutically acceptable salt thereof, and a stabilizer, wherein the stabilizer is an antioxidant and/or more susceptible to nucleophilic attack than the antineoplastic compound.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 18, 2014
    Inventors: Mahmoud S. AlSwisi, Mahmoud A.A. Ghannam